{"id":390134,"date":"2020-12-11T00:00:00","date_gmt":"2020-12-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0008-2020-biopharma-immune-checkpoint-inhibitors-trends-and-market-dynamics-special-topics-g7-2020\/"},"modified":"2026-04-22T05:22:40","modified_gmt":"2026-04-22T05:22:40","slug":"sptoon0008-2020-biopharma-immune-checkpoint-inhibitors-trends-and-market-dynamics-special-topics-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0008-2020-biopharma-immune-checkpoint-inhibitors-trends-and-market-dynamics-special-topics-g7-2020\/","title":{"rendered":"Immune Checkpoint Inhibitors: Trends and Market Dynamics | Special Topics | G7 &#8211; 2020"},"content":{"rendered":"<p>Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of agents targeting checkpoint blockade continues to transform the treatment paradigm for many oncology indications at an incredible rate. This <em>Special Topics<\/em> report provides a comprehensive market forecast of current and emerging immune checkpoint inhibitors and analyzes the market trends and dynamics in a range of oncology indications.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the timeline and current landscape for approved immune checkpoint inhibitors? What are the trends in each key oncology indication?<\/li>\n<li>How will emerging immune checkpoint inhibitors be positioned in the market? How will the indication-specific market trends and dynamics evolve?<\/li>\n<li>What is the commercial potential of current and emerging immune checkpoint inhibitors by brand, indication, combination type, and geography? How will the market evolve over the 2020-2030 forecast period?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHIES<\/strong><\/p>\n<p>United States, EU5, Japan.<\/p>\n<p><strong>EPIDEMIOLOGY<\/strong><\/p>\n<p>Drug-treated patient populations by brand, indication, combination type, and geography for indications for which immune checkpoint inhibitors are approved or forecast for approval.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2030, segmented by indication, combination type, and geography.<\/p>\n<p><strong>KEY DRUGS COVERED<\/strong><\/p>\n<p>Currently approved agents targeting PD-1, PD-L1, and CTLA-4.<\/p>\n<p><strong>EMERGING THERAPIES<\/strong><\/p>\n<p>Phase III\/PR.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Clarivate\u2019s <em>Special Topics<\/em> reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications<\/p>\n","protected":false},"template":"","class_list":["post-390134","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-special-topics-other","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390134\/revisions"}],"predecessor-version":[{"id":393259,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390134\/revisions\/393259"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}